Na letošních XXXV. olomouckých hematologických dnech bude možné opět potkat a vyslechnout si přednášky řady zajímavých a výjimečných zahraničních hostů.
Jennifer R. Brown, MD, PhD
Professor of Medicine, the Director of the CLL Center of the Division of Hematologic Malignancies at Dana‐Farber Cancer Institute and the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts
Dr. Brown is internationally recognized as a key leader in the revolution in chronic lymphocytic leukemia (CLL) therapy in the last several years, with the development of the targeted oral inhibitors of the BCR and BCL‐2 families. Her work has fundamentally changed therapy for the disease, with seminal publications leading to the FDA approvals of ibrutinib and idelalisib. She has also made seminal translational observations on genomic predictors of response to ibrutinib, and on the mechanisms of idelalisib activity, including the unusual pattern of response, the autoimmune toxicity and the association of that toxicity with a decrease in regulatory T cells. She is also a leader in both the somatic and germline genomic understanding of CLL. Her long‐term commitment to studying the germline heritability of CLL led to the first large‐scale study evaluating rare germline variation as a contributor to CLL development, and in so doing definitively implicated rare variation in ATM in the causation of CLL.
Irit Avivi, MD, PhD
Professor of Medicine; Director of Hematology division at Sourasky Tel Aviv Medical Center
Dr. Avivi has an extensive experience in working with pharma and start‐up companies; defining study's endpoints and patient population, designing, writing, conducting and leading investigator initiated/pharma sponsored multicenter clinical studies. She is a medical advisor of international and national pharma companies as well as start‐up companies involved in developing digital imaging technologies, new small cell molecules, cellular therapies and diagnostic platforms.
Her major research and clinical expertise are in clinical and basic studies in multiple myeloma and clinical studies in lymphoma, including the employment of immune‐modulating strategies e.g. dendritic cell fusion vaccine, regulatory cell depletion, CART cells etc.), cancer‐related immunodeficiency, B cell depletion and rejuvenation, infections related to cancer/therapy‐related immunodeficiency, managing hematological cancers during pregnancy and fertility preservation in young women planned for chemotherapy
Veronika Bachanova, MD, PhD
Professor of Medicine; Lead of Lymphoma Interdisciplinary Team at University of Minnesota Cell Therapies Clinical Director Section Head, Malignant Hematolog
Veronika Bachanova is a physician‐scientist and an Professor in the Division of Hematology, Oncology, and Transplantation at the University of Minnesota Medical School. She received her medical degree from Comenius University in Slovakia and completed her residency training in Internal Medicine at Mayo Clinic in Rochester, MN. She subsequently completed her Hematology/Oncology fellowship training at the University of Minnesota, where she also earned her PhD in Molecular, Cellular, and Developmental Biology. Dr. Bachanova's research focuses on developing novel immunotherapeutic approaches to treat cancer, with a particular interest in hematological malignancies such as lymphoma and leukemia. She has been the principal investigator or co‐investigator on several clinical trials investigating the use of CAR T‐cell therapy and other immunotherapies in these diseases. Her work has been published in numerous high‐impact scientific journals, and she has been invited to present her research at national and international conferences. In addition to her research, Dr. Bachanova is an active clinician, caring for patients with hematological malignancies at the University of Minnesota Medical Center. She is also involved in teaching and mentoring medical students, residents, and fellows.
Karolis Šablauskas, MD, PhD
Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
Dr Karolis Šablauskas is a resident physician in clinical genetics at Vilnius University and Radboud University Medical Center. Together with Vilnius University Team he has won gold medal in the iGEM (International Genetically Engineered Machine) competition in 2016 and the grand prize in 2017. Dr Šablauskas was the Chairman of Lithuanian Junior Doctors Association in 2018 and teaches the course “AI for Medical Doctors”. He is a self‐taught AI specialist combining the machine learning expertise with his medical knowledge.
Mano Joseph Mathew, MD, PhD
EFREI Research Lab, EFREI Paris Panthéon‐Assas Université, Laboratoire Génomique, Bioinformatique, et Chimie Moléculaire (GBCM EA7528), Conservatoire National des Arts et Métiers (CNAM), Paris, France.
Dr. Mathew is a research professor and head of the Master program Bioinformatics at EFREI Paris Panthéon‐Assas Université. His research expertise is in epigenomic reprogramming in cancer, system’s biology and multiomics data integration, high‐throughput genomics Chip‐Seq, RNA‐Seq and ExomeSeq data and AI powered healthcare.
